KAUST startup Wayakit has partnered with Swissport International AG to provide its disinfecting products at Jeddah, Dammam, and Riyadh airports. Wayakit's antiviral formulation eliminates 99.999% of bacteria, viruses, and the SARS-CoV-2 strain in 30 seconds. Swissport will use Wayakit to disinfect aircraft and buses, helping to curb the spread of COVID-19 and restore passenger confidence. Why it matters: This partnership highlights the growth of the Saudi startup ecosystem and KAUST's role in fostering innovation and supporting local entrepreneurs in developing advanced biotechnological solutions for critical challenges.
KAUST researchers are developing iSCAN, a rapid, field-deployable COVID-19 test using RT-LAMP coupled with CRISPR-Cas12. The iSCAN system is designed for rapid, specific detection of SARS-CoV-2 and can be deployed by untrained personnel. The researchers are benchmarking iSCAN against commercial kits and seeking emergency use authorization from the Saudi FDA. Why it matters: A rapid, accurate, and field-deployable COVID-19 test could significantly improve pandemic management and control in Saudi Arabia and beyond.
KAUST responded to the COVID-19 pandemic by focusing on scientific research and innovation, including pivoting existing startups to address new challenges. Wayakit, a KAUST startup, adapted its disinfectant product for safer air travel and partnered with Swissport International for use in Saudi airports. KAUST also joined the University-Industry Demonstration Partnership (UIDP) and the Stanford-led Open IP Access Framework to accelerate technology transfer. Why it matters: This highlights the role of research universities in rapidly translating scientific findings into practical solutions during crises, and KAUST's efforts to bridge academia and industry.
SaudiVax, located in the KAUST Research & Technology Park, is collaborating with the University of Pittsburgh and Merck France to develop a COVID-19 antibody injection. The antibody both protects against potential infection and neutralizes the virus in those already infected. SaudiVax is utilizing KAUST expertise and has contracted with Merck France for manufacturing since suitable facilities are not yet available in Saudi Arabia. Why it matters: This partnership highlights the growing biopharmaceutical capabilities in Saudi Arabia and the potential for KAUST to serve as a hub for medical innovation in the region.
KAUST researchers have developed an energy-efficient wastewater treatment process that generates high-quality effluent suitable for reuse. A pilot plant in Jeddah, operating since July 2022 in collaboration with MODON, treats 50,000 liters of wastewater daily off-grid, generating 1.5 kWh of electrical energy per 1,000 liters treated. The plant utilizes an anaerobic membrane bioreactor (AnMBR) coupled with UV disinfection, removing up to 99.9999% of microorganisms and producing less solid waste. Why it matters: This decentralized, energy-independent system offers a sustainable solution for water treatment in resource-scarce regions of the Middle East, aligning with Saudi Arabia's sustainability goals.
KAUST startup Wayakit has inaugurated its first production pilot plant in Saudi Arabia, with a capacity of up to 20,000 liters of cleaning and disinfection bio-formulations per day. The plant aims to satisfy national demand for cleaning and disinfection products. Wayakit's products tackle the transmission of communicable diseases, contributing to both the national economy and the health of citizens. Why it matters: This pilot plant supports Saudi Vision 2030's National Industrial Strategy by building a sustainable facility for environmentally friendly cleaning products.
KAUST Associate Professor Peiying Hong delivered a lecture on using wastewater testing to detect outbreaks earlier. The lecture explains how wastewater testing could lead to faster detection and more effective response to future pandemics. The research was presented at King Abdullah University of Science and Technology. Why it matters: Wastewater epidemiology can provide early warnings for emerging pathogens and improve public health preparedness in the region.
KAUST's Rapid Research Response Team (R3T), including Professor Samir Hamdan, is working to understand and counteract the spread of COVID-19. The team assembled a complete homemade, one-step RT-PCR test, comparable to commercial kits, with a patent-free manufacturing recipe. KAUST R3T is also researching faster, more accurate point-of-care tests, including a CRISPR-based molecular test. Why it matters: This research provides accessible testing solutions and contributes to more effective and rapid detection methods for combating viral spread in the region and globally.